Failure of Bacillus Calmette Guerin (BCG) therapy for the treatment of bladder cancer: Al-Azhar experience (original) (raw)
Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer
Zoran Dogas
Croatian medical journal, 2003
View PDFchevron_right
The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma
Jitendra Goyal
Urology, 2007
View PDFchevron_right
Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder
Jack Baniel
Urology, 1998
View PDFchevron_right
The side effects of bacillus calmette-guerin in the treatment of TA Ti bladder cancer do not predict its efficacy: Results from an eortic genito-urinary group phase III trial
giovanni casetta
European Urology Supplements, 2003
View PDFchevron_right
Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer
G. Barbalias
International Urology and Nephrology, 1990
View PDFchevron_right
Long-term results of intravesical bacillus calmette-guérin therapy for stage T1 superficial bladder cancer
Hagen Loertzer
Urology, 2000
View PDFchevron_right
Maintenance bacillus calmette-guerin for TA, T1 bladder cancer is not associated with increased toxicity, results from an eortc genito-urinary group phase III trial
giovanni casetta
European Urology Supplements, 2003
View PDFchevron_right
The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
Giovanni Casetta
European Urology, 2003
View PDFchevron_right
Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
Giovanni Casetta
European Urology, 2003
View PDFchevron_right
Control Group and Maintenance Treatment With Bacillus Calmette-Guerin for Carcinoma In Situ and/or High Grade Bladder Tumors
Pilar Laguna
The Journal of …, 2001
View PDFchevron_right
Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review
Peter Gilling
International journal of urology : official journal of the Japanese Urological Association, 2017
View PDFchevron_right
A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer: INTRAVESICAL BCG PLUS TUR VS TUR ALONE IN Ta AND T1 BLADDER CANCER
Bernadette Coles
Bju International, 2001
View PDFchevron_right
Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer
Michael Cookson
Reviews in urology, 2008
View PDFchevron_right
The clinical course of non-muscle invasive bladder cancer after transuretral resection of the tumor with or without subsequent intravesical application of bacillus Calmette-Guérin: The influence of patients gender and age
Miodrag Lazić
Vojnosanitetski pregled, 2015
View PDFchevron_right
Non-muscle invasive bladder cancer and bacillus Calmette-Guerin treatment: a review of the literature
Jason Alcorn
British Journal of Urological Nursing, 2014
View PDFchevron_right
Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
Esther Julián
ImmunoTargets and Therapy
View PDFchevron_right
Completion of Maintenance Bacillus Calmette-Guerin Therapy Might Prolong Recurrence-Free Survival in Patients with Non Muscle Invasive Bladder Cancer
zaher bahouth
Open Journal of Urology, 2015
View PDFchevron_right
Clinical outcomes in a cohort of patients with T1 high grade urothelial bladder cancer not receiving intravesical bacillus Calmette-Guerin: a 15 year experience
HMKB Herath
View PDFchevron_right
Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies
Rikiya Taoka
Cancers, 2021
View PDFchevron_right
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer
Kehu Yang
Reviews, 1996
View PDFchevron_right
Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)
Archan Khandekar
Asian Journal of Urology, 2022
View PDFchevron_right
A 12 VERSUS 6-WEEK COURSE OF BACILLUS CALMETTE-GUERIN PROPHYLAXIS FOR THE TREATMENT OF HIGH RISK SUPERFICIAL BLADDER CANCER
Ilan Gruenwald
View PDFchevron_right
The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer
Marco Oderda
European Urology, 2010
View PDFchevron_right
A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non–muscle-invasive bladder cancer
Sunil Shewale
Urologic Oncology: Seminars and Original Investigations, 2020
View PDFchevron_right
Real‐world treatment patterns and clinical outcomes of Japanese patients with non‐muscle invasive bladder cancer receiving intravesical bacillus Calmette–Guérin treatment
Nobuya Hayashi
International Journal of Urology, 2022
View PDFchevron_right
Effective dose and adverse effects of maintenance Bacillus Calmette-Gue'Rin in intermediate and high risk non-muscle invasive bladder cancer: a meta-analysis of randomized clinical trial
Ahmad Zulfan
2014
View PDFchevron_right
Intravesical Bacillus Calmette-Guerin Treatment Improves Patient Survival in T1G3 Bladder Tumours
Alejandro Rodríguez
European Urology, 2002
View PDFchevron_right